ALARIS Medical Launches Web Based Medication Safety and Clinical Improvement Resource.

Business Editors & Health/Medical Writers

SAN DIEGO--(BUSINESS WIRE)--Jan. 30, 2003

New Online Site Designed to Help Reduce Medication Errors Through

Education and Technological Innovation

ALARIS Medical Systems Inc., a wholly owned subsidiary of ALARIS Medical Inc. (AMEX:AMI), announced today the launch of the ALARIS(R) Center for Medication Safety and Clinical Improvement (The ALARIS(R) Center) online site: http://www.alarismed.com/alariscenter/index.html.

The Medication Safety and Clinical Improvement site is an online extension of the recently launched ALARIS(R) Center. The principal mission of both the ALARIS(R) Center and its online site is to raise awareness among health care professionals of the risk of harm associated with critical drug delivery errors, to advance clinical best practices and to support institutions' efforts to attain the highest levels of patient and caregiver safety. The new Web based resource provides user-friendly tools and educational resources to help institutions reduce the risk of point-of-care medication errors and meet their specific safety goals.

"We have developed what we believe is a unique online resource that provides information, education and consulting services to the entire health care industry. It holds tremendous potential for helping hospitals, clinicians, nurses, pharmacists and administrators deal with the growing problem of medication safety," said Dave Schlotterbeck, president and CEO of ALARIS Medical Systems.

"The ALARIS(R) Center's new online site promotes and encourages best practices for medication safety, and will assist hospitals in their efforts to achieve impactful clinical improvement," continued Schlotterbeck.

The ALARIS(R) Center Web based resource offers a variety of medication safety and clinical improvement information including:

-- Consulting and Training Services; a comprehensive coordination of medication safety system implementation process, professional leadership and clinical expertise related to infusion therapy and medication safety.

-- Failure Mode & Effects Analysis (FMEA); designed to help hospitals not only exceed Joint Commission on Accreditation of Healthcare Organizations (JCAHO) requirements, but to support their on-going process improvement initiatives. FMEA is a systematic method of identifying and averting process or product issues before they occur.

-- Presentations and Conferences; information on past and upcoming ALARIS(R) Center sponsored symposium and conferences with reports from medication safety thought leaders.

-- Medication Safety Education; information to broaden knowledge base of the issues regarding medication safety at the point of care and provide practical and innovative solutions that will help institutions achieve their medication safety goals.

-- Medication Safety e-Library; a compilation of medication error news and a list of recommended readings.

About ALARIS Medical Inc.

ALARIS Medical Inc. (AMEX:AMI), through its wholly owned operating company, ALARIS Medical Systems Inc., develops practical solutions for medication safety at the point of care. The company designs, manufactures and markets intravenous (IV) medication delivery and infusion therapy devices, needle-free disposables and related monitoring equipment. ALARIS Medical's "smart" technology, tools and services reduce the risks and costs of medication errors, and safeguard patients and clinicians. The company provides its products, professional and technical support and training services to over 5,000 hospital and health care systems, as well as alternative care sites in more than 120 countries through its direct sales force and distributors. Headquartered in San Diego, ALARIS Medical employs approximately 2,600 people worldwide and operates manufacturing facilities in the United States, Mexico and the United Kingdom.

This news release contains forward-looking statements as defined in the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Persons reading this release are cautioned that such forward-looking statements involve risks and uncertainties, including the effect of legislative and regulatory changes affecting the health care industry, the potential of increased levels of competition, technological changes, the dependence of ALARIS Medical upon the success of new products (including its proprietary Guardrails(R) Safety Software and the MEDLEY(TM) Medication Safety System) and ongoing research and development efforts including obtaining regulatory approvals, restrictions contained in the instruments governing the Company's indebtedness, and the significant leverage to which the Company is subject. Such risk factors are detailed in the Securities and Exchange Commission filings of ALARIS Medical, Inc. and ALARIS Medical Systems, Inc., including Forms 10-K for the year ended December 31, 2001, and other filings. The Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments.